Preoperative Preradiotherapy TTFields
- Conditions
- Glioblastoma
- Interventions
- Device: TTFields
- Registration Number
- NCT06136611
- Lead Sponsor
- The Christie NHS Foundation Trust
- Brief Summary
PreOperative PreRAdIotherapy Tumour Treating Fields (PORTRAIT) is a Phase I study that will test the safety and feasibility of Optune administered preoperatively and preradiotherapy in patients with a new radiological diagnosis of glioblastoma (GBM). Participants will be required to undergo additional MRI sequencing scans and provide blood, tear fluid and tissue samples over a maximum of 6 months. After the study patients will follow their standard treatment pathway.
- Detailed Description
Glioblastoma is the most common primary malignant brain tumour in adults. Its outcomes are poor due to local disease progression in most patients. Current treatment includes surgery followed by chemotherapy and radiotherapy 4-6 weeks after surgery. In this time interval, some tumour cells do not receive any treatment. Furthermore, studies show that around half of all glioblastoma patients experience rapid early progression (REP) i.e. growth of the tumour in the time interval between surgery and postoperative chemotherapy/radiotherapy. REP is associated with a shorter survival and there are currently no effective treatments or preventative measures to address it.
Tumour Treating Fields (TTFields), also known as Optune, is a locally applied treatment modality that has contributed to a better survival outcome for glioblastoma patients when used after surgery and chemo-radiotherapy. We hypothesize that earlier treatment using the Optune device before the surgery and between the surgery and postoperative radiotherapy can prevent REP and improve patient outcome. In this phase 1 trial, PORTRAIT (PreOpeRaTive pRerAdIotherapy Ttfields), we will test the safety and feasibility of Optune treatment before surgery and before post-operative radiotherapy in a maximum of 14 patients. Participants will be required to undergo additional MRI sequencing scans and provide blood, tear fluid and tissue samples over a maximum of 6 months.
To maximise PORTRAIT's translational and clinically relevant components, a non-experimental arm (Non-EA) of 28 patients will allow comparisons of data collected from PORTRAIT patients with comparable Standard of Care (SoC) treated patients from the same time frame.
Participants will be invited to the research study if they are over the age of 35 and have a new radiological diagnosis of glioblastoma. All recruitment and treatment will be conducted at the Christie NHS Foundation Trust and Northern Care Alliance NHS Foundation Trust.
The study is funded by a research grant from Novocure.
Recruitment & Eligibility
- Status
- NOT_YET_RECRUITING
- Sex
- All
- Target Recruitment
- 42
- Patient is aged >35 years (age range of more likely to suffer from an IDHwt WHO grade 4 astrocytoma)*
- Patient is male or female.
- Patient has a new radiological diagnosis of glioblastoma.
- Patient has a performance status judged by World Health Organisation, Eastern Cooperative Oncology Group [ECOG] score = 0-1.
- Patient has been reviewed by Neuro-oncology multidisciplinary team (MDT - neurosurgeon, clinical oncologist, radiologist and pathologist); MDT consensus that offering study entry is clinically appropriate and safe i.e. patient unlikely to come to harm (e.g. hydrocephalus) from delayed surgery and pre-operative Optune based on available clinical information and imaging.
- PI has confirmed at the first clinic visit that study entry is clinically appropriate and safe (e.g. lack of severe and debilitating symptoms of raised intracranial pressure).
- There is intention to treat the patient with surgical resection and postoperative adjuvant therapy as per current standard of care (40Gy/15 fr or 60Gy/30fr).
- Patient has adequate haematological and biochemical parameters for surgery and contrast agent administration (full blood count and coagulation profile deemed acceptable by clinical team, eGFR >30ml/min).
- Patient has mental capacity to consent for treatment.
- Patient is able and willing to give informed consent
Criteria specific to the experimental arm:
- Patient is able and willing to comply with study protocol requirements to continuously shave their head
- Patient is able and willing to comply with study protocol requirements to wear Optune equipment for the required duration.
- Patients with uncontrolled seizures.
- Patients are due to undergo a planned biopsy procedure only.
- Patients have a suspicion of other tumour on CT body scan or known malignancy except non-melanoma skin cancer, completely resected or prostate cancer (with Prostate Specific Antigen of less than or equal to 0.1 ng/ml) within the past three years.
- Patients have contraindications to contrast-enhanced MRI scanning (e.g. claustrophobia, gadolinium allergy).
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Optune TTFields Patients will apply TTFields (a treatment device referred to as Optune) before surgery and continue using this once the stitches are removed (approximately one to two weeks after surgery). Patients will wear the Optune application for 2 to 3 weeks before their standard-of-care (SoC) surgery and 3 to 4 weeks after the surgery (while awaiting their postoperative radiotherapy). Treatment with TTFields will be delivered through 4 transducer arrays with 9 insulated electrodes each placed on the shaved scalp and connected to a portable device set to generate 200-kHz electric fields within the brain.
- Primary Outcome Measures
Name Time Method To determine the incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] of Pre-Operative and Pre-Radiotherapy TTFields additional to the standard treatment of care (SoC) including adjuvant TTFields. 18 months This endpoint will be tested by alterations to the original date of surgery and the start of the postoperative radiotherapy;
Study related complications will be defined as;
* Change of surgery date due to symptoms related to the tumour that are possibly related to the TTFields treatment
* Delay of start of the postoperative RT possibly related to the TTFields treatment (later than 6 weeks postoperative)
- Secondary Outcome Measures
Name Time Method Skin reactions 18 month Skin reactions defined by CTCAE V5.0 - a rating scale of 1 to 5. 1 indicates minimal toxicity (skin irritation etc), 5 indicates death - or life threatening complications.
Registration of postoperative surgical complications 18 months Postoperative surgical complications (e.g. haemorrhage, wound infection, delayed wound healing, seizures). Lower registrations represents a better outcome.
Registration of radiotherapy related complications 18 months Radiotherapy related complications (e.g. radiation necrosis). Lower registrations represents a better outcome.
Overall survival 18 months Time period from the date of surgery to the date of death. A longer time period represents a better outcome.
Concordance between MRI based diagnosis of glioblastoma and definitive histological diagnosis 18 months Evaluate the use of MRI to select glioblastoma patients for PORTRAIT without pathological confirmation.
REP: tumour volume difference between the post-operative MRI and pre-radiotherapy MRI. 18 months Evaluate the effect of TTFields on REP - tumour growth between surgery and postoperative chemoradiotherapy, in patients with a new diagnosis of glioblastoma. A lower value represents a better outcome.
Steroid dose after TTFields 18 months Steroid dose recorded after TTFields until the start of the postoperative RT. Lower (or absence of) dose represents a better outcome.
Progression free survival 18 months Time period from the date of surgery to the date of the MRI scan demonstrating first progression as determined by the neuro-oncology MDT. A longer time period represents a better outcome.
Collection of liquid biopsies 18 months Collection of blood and tear fluid samples at matched imaging timepoints.